Navigation Links
Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
Date:9/16/2013

BOSTON, Sept. 16, 2013 /PRNewswire/ -- Benu BioPharma announced today the establishment of Benu BioVentures, a new biopharmaceutical investment initiative to fund and develop preclinical stage pharmaceutical investments to the human proof-of-concept stage.  Leveraging Benu BioPharma's management expertise in technology commercialization and pharmaceutical development, Benu BioVentures is creating and financing virtual companies that will develop candidate drugs in a cost and time efficient manner.  Funding activities will focus on product candidates with strong animal data and a clear regulatory path that address unmet medical needs.  Benu BioVentures is led by Dennis Goldberg, Ph.D., FAHA and Fred Meyer, Ph.D., CFA, both recognized biopharmaceutical serial entrepreneurs. 

According to Dennis Goldberg, Co-Founder and Partner, "With our clinical, regulatory and corporate development capabilities, we can offer founders a unique solution to the current funding gap for product focused start-ups.  We collaborate with founders to move their drug candidates into the clinic and then partner with a large pharma or biotech company to complete development." 

Bios

Dennis Goldberg, Ph.D., FAHA

Dennis Goldberg is a biotechnology and pharmaceutical drug development executive and entrepreneur with more than 25 years of experience in these industries, ranging from drug discovery at a Fortune 25 pharmaceutical company to President and CEO of multiple "virtual" biotechnology companies.  He is President and co-founder of Benu BioPharma, a biotechnology product development management and consulting firm. Benu currently provides full management services for two virtual biotech companies.

Fred Meyer, Ph.D., CFA

Fred Meyer specializes in strategy, finance, and business development within life science industries.  Over the past 16 years, he co-founded Artisan Pharma, Exponential Pharma Partners, and LipimetiX Development, where he currently supports business development. At Apeiron Partners, he provided strategic advice to early and mid-stage ventures, designed and implemented financings, key technology licenses, and partnership deals for clients. Fred previously performed biotechnology equity research at Needham & Company and business development for the portfolio companies of Schooner Capital.

About Benu BioVentures (www.benubio.com)

Benu BioVentures, based in Natick, Massachusetts, utilizes a virtual company model to move validated candidate drugs into the clinic and establish human safety and efficacy.  The experienced development team collaboratively works with founders to demonstrate human proof of concept in a cost and time efficient program.  Benu focuses on creating a data package that will be sufficient to license/partner with larger companies, who will be responsible for completing clinical development and marketing developed drugs.  Benu BioVentures is actively seeking opportunities in human biopharmaceuticals. 

About Benu BioPharma (www.benubio.com)

Benu BioPharma is a biopharmaceutical development management and consulting company, that provides the essential functional expertise for drug development with the efficiency, nimbleness and speed that is critical to success for an entrepreneurial organization.  The company is based in Natick, Massachusetts.


'/>"/>
SOURCE Benu BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
2. Cato Research and Cato BioVentures Announces the Opening of Houston, Texas, Office
3. Join Cato BioVentures at BIO International Convention
4. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
5. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
6. Ultragenyx Appoints Shalini Sharp as Chief Financial Officer and Senior Vice President, Finance
7. Oxford Finance Completes $271.4 Million Securitization Transaction
8. A Genetic Approach For Crohns And Colitis Disease Is Financed By The Jeffrey Epstein VI Foundation
9. Israeli Ministry of Finance Hosts Israel Investment, Innovation and Trade Forum in New York
10. Sudanese 'lost Boy' Who Became Finance Minister to Receive Prestigious Alumni Award from Johns Hopkins
11. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
Breaking Biology Technology:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not ... one of the most crucial aspects of recovery so we need to do it ... health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... sleep and find a Christmas present that could help them to manage their sleep ... ...
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):